Last reviewed · How we verify
Grazaoprevir/Elbasavir/RBV
Grazoprevir inhibits hepatitis C virus NS3/4A protease while elbasavir inhibits NS5A protein, and ribavirin acts as a nucleoside analog to inhibit viral replication.
Grazoprevir inhibits hepatitis C virus NS3/4A protease while elbasavir inhibits NS5A protein, and ribavirin acts as a nucleoside analog to inhibit viral replication. Used for Chronic hepatitis C virus infection (genotype 1, 4, 5, 6).
At a glance
| Generic name | Grazaoprevir/Elbasavir/RBV |
|---|---|
| Sponsor | The HIV Netherlands Australia Thailand Research Collaboration |
| Drug class | Direct-acting antiviral (DAA) combination; NS3/4A protease inhibitor + NS5A inhibitor + nucleoside analog |
| Target | HCV NS3/4A protease; HCV NS5A protein; viral RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Virology/Hepatology |
| Phase | FDA-approved |
Mechanism of action
This is a direct-acting antiviral (DAA) combination therapy for hepatitis C. Grazoprevir blocks the NS3/4A serine protease essential for HCV polyprotein processing, while elbasavir targets the NS5A protein required for viral replication and assembly. Ribavirin enhances antiviral activity through multiple mechanisms including mutagenesis of the viral genome.
Approved indications
- Chronic hepatitis C virus infection (genotype 1, 4, 5, 6)
Common side effects
- Headache
- Fatigue
- Nausea
- Anemia (ribavirin-related)
- Elevated bilirubin
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: